WO2000016754A3 - Antiviral combinations comprising lamivudine and lobucavir - Google Patents

Antiviral combinations comprising lamivudine and lobucavir Download PDF

Info

Publication number
WO2000016754A3
WO2000016754A3 PCT/EP1999/006884 EP9906884W WO0016754A3 WO 2000016754 A3 WO2000016754 A3 WO 2000016754A3 EP 9906884 W EP9906884 W EP 9906884W WO 0016754 A3 WO0016754 A3 WO 0016754A3
Authority
WO
WIPO (PCT)
Prior art keywords
lobucavir
lamivudine
combinations
hydroxymethyl
amino
Prior art date
Application number
PCT/EP1999/006884
Other languages
French (fr)
Other versions
WO2000016754A2 (en
Inventor
Nathaniel A Brown
Lynn D Condreay
Douglas Fraser Gray
Marc Rubin
Original Assignee
Glaxo Group Ltd
Nathaniel A Brown
Lynn D Condreay
Douglas Fraser Gray
Marc Rubin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Nathaniel A Brown, Lynn D Condreay, Douglas Fraser Gray, Marc Rubin filed Critical Glaxo Group Ltd
Priority to AU61919/99A priority Critical patent/AU6191999A/en
Publication of WO2000016754A2 publication Critical patent/WO2000016754A2/en
Publication of WO2000016754A3 publication Critical patent/WO2000016754A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to therapeutic combinations comprising (2R,cis)-4- amino-1- (2-hydroxymethyl -1,3-oxathiolan -5-yl) -pyrimidin-2 -one (lamivudine) and a second therapeutic agent [1R- (1α,2β,3α)] -2-amino -9-[2,3-bis (hydroxymethyl) cyclobutyl] -1,9 -dihydro -6H- purin- 6-one, (lobucavir). The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HBV infections including infections with HBV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors of the replication of the hepatitis B virus.
PCT/EP1999/006884 1998-09-18 1999-09-17 Antiviral combinations comprising lamivudine and lobucavir WO2000016754A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU61919/99A AU6191999A (en) 1998-09-18 1999-09-17 Antiviral combinations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9820416.7 1998-09-18
GBGB9820416.7A GB9820416D0 (en) 1998-09-18 1998-09-18 Antiviral combinations

Publications (2)

Publication Number Publication Date
WO2000016754A2 WO2000016754A2 (en) 2000-03-30
WO2000016754A3 true WO2000016754A3 (en) 2000-08-03

Family

ID=10839130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/006884 WO2000016754A2 (en) 1998-09-18 1999-09-17 Antiviral combinations comprising lamivudine and lobucavir

Country Status (3)

Country Link
AU (1) AU6191999A (en)
GB (1) GB9820416D0 (en)
WO (1) WO2000016754A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1267880T2 (en) 2000-02-29 2010-04-30 Bristol Myers Squibb Co Low dose entecavir formulation and use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032490A1 (en) * 1997-12-19 1999-07-01 Bristol-Myers Squibb Company Prodrugs of lobucavir and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032490A1 (en) * 1997-12-19 1999-07-01 Bristol-Myers Squibb Company Prodrugs of lobucavir and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ONO-NITA S.K. ET AL: "Susceptibility of lamivudine resistant hepatitis B virus to other antivirals; Adefovir and Lobucavir", HEPATOLOGY, vol. 28, no. 4/2, October 1998 (1998-10-01), pages 165a, XP002135790 *
SO SAMUEL K. ET AL.: "Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 14/SUPPL., May 1999 (1999-05-01), AUSTRALIA, pages 48 - 52, XP000885882 *

Also Published As

Publication number Publication date
AU6191999A (en) 2000-04-10
GB9820416D0 (en) 1998-11-11
WO2000016754A2 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
TW366347B (en) Antiviral pharmaceutical compositions comprising 1,3-oxathiolane nucleoside analogues
RU94013464A (en) NUCLEOSIDE ANALOGUES 1,3-OXATIOLANE, METHOD OF OBTAINING, PHARMACEUTICAL COMPOSITION, METHOD OF TREATING VIRAL INFECTION
EP1062950A3 (en) 1,3 Oxathiolane nucleoside analogues
MY115461A (en) Synergistic combinations of zidovudine, 1592u89 and 3tc
EP1808434A3 (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine fo the treatment of hepatitis B
IL101836A0 (en) Pharmaceutical compositions containing 1,3-oxathiolane nucleoside derivatives
BR9811121A (en) Product, pharmaceutical composition, and use of a product
MX9200747A (en) ANTIVIRAL ACTIVITY AND RESOLUTION OF 2-HYDROXIMETHYL ANTIVIRAL ACTIVITY AND RESOLUTION OF 2-HYDROXIMETHYL-5 (5-FLUOROCYTOSIN-1-IL) -1,3-OXATIOLANE. -5 (5-FLUOROCYTOSIN-1-IL) -1,3-OXATIOLANE.
CA2445744A1 (en) Antiviral nucleoside derivatives
WO1998042321A3 (en) Liquid compositions comprising lamivudine
EA200000997A1 (en) HOMOGENEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING ABAKAVIR, LAMIVUDIN AND ZIDOVUDIN
HUP9903249A2 (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
WO2000016755A3 (en) Antiviral combinations of lamivudine and adefovir
WO2001030329A3 (en) Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction
WO2000016754A3 (en) Antiviral combinations comprising lamivudine and lobucavir
IE893991L (en) 2',3'-dideoxypurine nucleoside/purine nucleoside¹phosphorylase inhibitor combination therapy and composition
DE69431304T2 (en) NUCLEOSIDES AND NUCLEOTIDES WITH ENLARGED RINGS
WO2000018383A3 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
AR005551A1 (en) A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING AN ANALOG NUCLEOSIDE AND IMMUNOSUPPRESSANTS IN COMBINATION WITH A CYTOTOXIC AGENT FOR THE TREATMENT OF INFECTIONS WITH THE SIMPLE HERPES VIRUS
CA2140238A1 (en) Antiviral combinations
Hanna FTC: antiretroviral in development
AR013424A1 (en) USE OF URIDINE FOR THE PREPARATION OF A USEFUL PHARMACEUTICAL COMPOSITION TO INHIBIT THE TOXICITY OF PIRIMIDINE ANALOGS
ECSP982450A (en) PHARMACEUTICAL COMPOSITIONS
WO2000018384A3 (en) Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir
TH84854A (en) Antiviral aggregates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase

Ref document number: 99948771

Country of ref document: EP

Kind code of ref document: A2